UK Markets closed

Zealand Pharma A/S (ZEAL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
29.25-0.98 (-3.24%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close30.23
Open29.73
Bid29.07 x 1000
Ask37.72 x 900
Day's range29.05 - 29.96
52-week range27.90 - 44.42
Volume2,390
Avg. volume16,638
Market cap1.321B
Beta (5Y monthly)0.88
PE ratio (TTM)N/A
EPS (TTM)-3.66
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est38.79
  • Globe Newswire

    Zealand Pharma A/S – Transaction Under Share Repurchase Program

    Company announcement – No. 47 / 2021 Zealand Pharma A/S – Transaction Under Share Repurchase Program Copenhagen, DK and Boston, MA, 20 July 2021 - On June 29, 2021, Zealand Pharma A/S ("Zealand") initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. Zealand has entered an a

  • Globe Newswire

    ZEALAND PHARMA A/S - TRANSACTIONS UNDER SHARE REPURCHASE PROGRAM

    Company announcement – No. 45/ 2021 ZEALAND PHARMA A/S - TRANSACTIONS UNDER SHARE REPURCHASE PROGRAM Copenhagen 6 July 2021 - On June 29, 2021, Zealand Pharma A/S ("Zealand") initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. Zealand has entered an arrangement with Dansk

  • Globe Newswire

    Total number of shares and voting rights in Zealand Pharma at June 30, 2021

    Company announcement – No. 44/ 2021 Total number of shares and voting rights in Zealand Pharma at June 30, 2021 Copenhagen, DK and Boston, MA, June 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of